CD8α status identifies human NK cell capacity for IL-15-induced proliferation and metabolism in a time-dependent fashion and exhibits a suppressive effect on NK cell activating receptors Journal of Clinical Investigation Fehniger Lab Celia Cubitt
jci.org/articles/view/…

Extensive genetic analysis of EBV+ nPTCL revealed frequent TET2 and DNMT3A mutations with a possible association with clonal hematopoiesis. ow.ly/7tSb50RGjPV #lymphoidneoplasia #hematopoiesisandstemcells

Induced CD8α identifies human NK cells with enhanced proliferative fitness and modulates NK cell activation

jci.org/articles/view/…

Happy to share our JVirology Editors release on the effects of TIGIT blockade on anti-SIV T and NK cell cytotoxicity in the NHP w/ implications for combination immunotherapy; a proud collab w/ the Sacha Lab National Primate Research Centers Vaccine & Gene Therapy Institute Weill Cornell Infectious Diseases Division

journals.asm.org/doi/10.1128/jv…

Paul Y. Song, MD, CEO of NKGen, comments on the advancement of SNK01 NK cell therapy into Phase 2 clinical development for the potential treatment of moderate #AlzheimersDisease . Read more about this important clinical milestone for the Company: bit.ly/3RgkVj1 $NKGN

This PET scan data shows from the left Amyloid Negative Cognitively Normal, Amyloid Positive Cognitively Normal, and Amyloid Positive Mild Cognitive Impairment

So in this cohort, amyloid positive participants showed a collapsed NK cell population

How does TGF-b regulate NK cell-based ADCC? Our study investigate the role of down regulation of CD16, leading to immuno suppression, and that TGF-b inhibition enhances NK cell ADCC. By our group’s stellar Joshua Wong, Gustavo Rossi and collaborators. Translational Research Institute UQ News

#新しいプロフィール画像

$NKGN 17:05 on May. 23 2024

NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

It was a notable week for the #celltherapy field.

🧫1st BLA for an allogeneic T-cell therapy was submitted to the FDA

🔬NK cell therapy to treat Alzheimer’s was cleared to start Phase II trials

🤝New strategic partnerships announced to advance cell therapy manufacturing
🧵1/6

Ph. 1 data of NKGen's SNK01 NK cell therapy, delivered in the highest dose to date, showed SNK01 demonstrated preliminary clinical benefit without any drug-related adverse events. Learn about the advancement of SNK01 into Ph. 2 clinical development: bit.ly/3RgkVj1 $NKGN

NK cell regulation of IgA in the intestine, check out the latest online now: mucosalimmunology.org/article/S1933-…

Innate Pharma announces advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 progressing to Phase 2 for blood cancer patients.

More info 👉 lnkd.in/ey9y2rqE

#InnatePharma #Immunotherapy #NKCell #Sanofi

Just published - important insights into the Natural Killer (NK) cell receptor interactions in bone marrow transplant patients. Fabulous collaborators Drs. Amir Toor and Elizabeth Krieger (Beth Krieger) EVMS Medicine Eastern Virginia Medical School

Explore a recent article that describes the differences between TMB, neoantigen load, PD-L1, CD4, and NK cell proportions according to MET mutation or amplification status.

bit.ly/44C61J4

Repeated doses of haploidentical expanded NK cell therapy were safe & well-tolerated without infusion adverse effects.
~60% of patients with refractory #AML achieved remission after administration of multiple doses of ex vivo expanded NK-cells #celltherapy
doi.org/10.1002/ajh.27…

Excited to share our latest publication in Science Immunology! We've uncovered an NK cell-mediated immune checkpoint (B7H6 : NKp30) that limits CAR T cell persistence, revealing new insights into immune regulation. #Immunology Broad Institute DKFZ
science.org/doi/10.1126/sc…

What a fantastic talk by Fernando Guimaraes on weaponizing NK cells for cancer immunotherapy. So many new insights and a beautiful analogy of NK cell activity 🐕🧫. This couldn't be better explained. #ASIAdvImmSchool Australian and New Zealand Society for Immunology #Immunotherapy